Antisocial personality disorder and opioid treatment outcomes: A review

Addictive Disorders and their Treatment

Volumn 4, Issue 3, 2005, Pages 85-97

  Havens, Jennifer R ^a   Strathdee, Steffanie A ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antisocial personality disorder; Heroin; Methadone; Opiate; Treatment

Indexed keywords

AMANTADINE; BENZODIAZEPINE; BUPRENORPHINE; CLONAZEPAM; COCAINE; DESIPRAMINE; DIAMORPHINE; METHADONE; NALTREXONE; OPIATE; PLACEBO;

BEHAVIOR THERAPY; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHADONE TREATMENT; OPIATE ADDICTION; PATIENT COUNSELING; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPATHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBSTANCE ABUSE; THERAPEUTIC COMMUNITY; TREATMENT OUTCOME;

EID: 24644490081     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.adt.0000155725.14375.6e     Document Type: Review

References (88)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. 4th ed. Washington, DC: American Psychiatric Association, 1994.
2. Kasen S, Cohen P, Skodol AE, et al. Childhood depression and adult personality disorder: alternative pathways of continuity. Arch Gen Psychiatry. 2001;58:231-236.
3. Loeber R, Burke JD, Lahey BB. What are adolescent antecedents to antisocial personality disorder? Crim Behav Ment Health. 2002;12:24-36.
4. Franken IH, Hendriks VM. Early-onset of illicit substance use is associated with greater axis-II comorbidity, not with axis-I comorbidity. Drug Alcohol Depend. 2000;59:305-308.
5. Ridenour TA, Cottler LB, Robins LN, et al. Test of the plausibility of adolescent substance use playing a causal role in developing adulthood antisocial behavior. J Abnorm Psychol. 2002;111:144-155.
6. Bernstein DP. Stein JA, Handelsman L. Predicting personality pathology among adult patients with substance use disorders: effects of childhood maltreatment. Addict Behav. 1998;23:855-868.
7. Luntz BK, Widom CS. Antisocial personality disorder in abused and neglected children grown up. Am J Psychiatry. 1994;151:670-674.
8. Marshall LA, Cooke DJ. The childhood experiences of psychopaths: a retrospective study of familial and societal factors. J Personal Disord. 1999;13: 211-225.
9. O'Connor TG, McGuire S, Reiss D, et al. Co-occurrence of depressive symptoms and antisocial behavior in adolescence: a common genetic liability. J Abnorm Psychol. 1998;107:27-37.
10. van den Bree MB, Svilds DS, Pickens RW Genetic influences in antisocial personality and drug use disorders. Drug Alcohol Depend. 1998;49:177-187.
11. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
12. Robins LN, Tipp J, Przybeck T. Antisocial Personality. In: Robins LN, Regier DA, editors. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York: Free Press, 1991:258-290.
13. Brooner R, King V, Kidorf M, et al. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:71-80.
14. Kosten TR, Rounsaville BJ, Kleber HD. DSM-III personality disorders in opiate addicts. Compr Psychiatry. 1982;23:572-581.
15. Strain EC, Brooner RK, Bigelow GE. Clustering of multiple substance use and psychiatric diagnoses in opiate addicts. Drug Alcohol Depend. 1991;27:127-134.
16. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264:2511-2518.
17. Brooner RK, Greenfield L, Schmidt CW et al. Antisocial personality disorder and HIV infection among intravenous drug abusers. Am J Psychiatry. 1993;150:53-58.
18. Dinwiddie SH, Reich T, Cloninger CR. Psychiatric comorbidity and suicidality among intravenous drug users. J Clin Psychiatry. 1992;53:364-369.
19. Dinwiddie SH, Cottler L, Compton W, et al. Psychopathology and HIV risk behaviors among injection drug users in and out of treatment. Drug Alcohol Depend. 1996;43:1-11.
20. Darke S, Hall W, Swift W. Prevalence, symptoms and correlates of antisocial personality disorder among methadone maintenance clients. Drug Alcohol Depend. 1994;34:253-257.
21. Darke S, Finlay-Jones R, Kaye S, et al. Anti-social personality disorder and response to methadone maintenance treatment. Drug Alcohol Rev. 1996;15: 271-276.
22. Bell J, Mattick R, Hay A, et al. Methadone maintenance and drug-related crime. J Subst Abuse. 1997;9: 15-25.
23. King VL, Kidorf MS, Stoller KB, et al. Influence of antisocial personality subtypes on drug abuse treatment response. J Nerv Ment Dis. 2001;189:593-601.
24. Rounsaville BJ, Weissman MM, Kleber H, et al. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry. 1982;39:161-168.
25. Rounsaville BJ, Tierney T, Crits-Christoph K, et al. Predictors of outcome in treatment of opiate addicts: evidence for the multidimensional nature of addicts' problems. Compr Psychiatry. 1982;23:462-478.
26. Rounsaville BJ, Kleber HD. Untreated opiate addicts. How do they differ from those seeking treatment? Arch Gen Psychiatry. 1985;42:1072-1077.
27. Rutherford MJ, Alterman AI, Cacciola JS, et al. Gender differences in diagnosing antisocial personality disorder in methadone patients. Am J Psychiatry. 1995;152:1309-1316.
28. Alterman AI, Cacciola JS. The antisocial personality disorder diagnosis in substance abusers: problems and issues. J Nerv Ment Dis. 1991;179:401-409.
29. Robins LN. The intimate connection between antisocial personality and substance abuse. Soc Psychiatry Psychiatr Epidemiol. 1998;33:393-399.
30. Gerstley LJ, Alterman AI, McLellan AT, et al. Antisocial personality disorder in patients with substance abuse disorders: a problematic diagnosis? Am J Psychiatry. 1990;147:173-178.
31. Bovasso GB, Alterman AI, Cacciola JS, et al. The prediction of violent and nonviolent criminal behavior in a methadone maintenance population. J Personal Disord. 2002;16:360-373.
32. Spitzer RL, Endicott J, Williams JB. Research diagnostic criteria. Arch Gen Psychiatry. 1979;36:1381-1383.
33. Cacciola JS, Rutherford MJ, Alterman AI, et al. Long-term test-retest reliability of personality disorder diagnoses in opiate dependent patients. J Personal Disord. 1998;12:332-337.
34. Calsyn DA, Wells EA, Fleming C, et al. Changes in Millon Clinical Multiaxial Inventory scores among opiate addicts as a function of retention in methadone maintenance treatment and recent drug use. Am J Drug Alcohol Abuse. 2000;26:297-309.
35. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51:253-263.
36. Cottler LB, Compton WM, Ridenour TA, et al. Reliability of self-reported antisocial personality disorder symptoms among substance abusers. Drug Alcohol Depend. 1998;49:189-199.
37. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. 3rd ed. Washington, DC: American Psychiatric Association, 1980.
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition Revision. Washington, DC: American Psychiatric Association. 1987.
39. Gill K, Nolimal D, Crowley TJ. Antisocial personality-disorder, HIV risk behavior and retention in methadone maintenance therapy. Drug Alcohol Depend. 1992;30:247-252.
40. Darke S, Kaye S, Finlay-Jones R. Drug use and injection risk-taking among prison methadone maintenance patients. Addiction. 1998;93:1169-1175.
41. Kelley JL, Petry NM. HIV risk behaviors in male substance abusers with and without antisocial personality disorder. J Subst Abuse Treat. 2000;19:59-66.
42. Compton WM, Cottler LB, Ben Abdallah A, et al. The effects of psychiatric comorbidity on response to an HIV prevention intervention. Drug Alcohol Depend. 2000;58:247-257.
43. Woody GE, Gallop R, Luborsky L, et al. HIV risk reduction in the National Institute on Drug Abuse Cocaine Collaborative Treatment Study. J Acquir Immune Defic Syndr. 2003;33:82-87.
44. Brooner R, Kidorf M, King V, et al. Drug abuse treatment success among needle exchange participants. Public Health Rep. 1998;113(Suppl 1):129-139.
45. Rounsaville BJ, Tierney T, Crits-Christoph K, et al. Predictors of outcome in treatment of opiate addicts: evidence for the multidimensional nature of addicts' problems. Compr Psychiatry. 1982;23:462-478.
46. Kaye S, Darke S. Finlay-Jones R. The onset of heroin use and criminal behaviour: does order make a difference? Drug Alcohol Depend. 1998;53:79-86.
47. Rounsaville BJ, Dolinsky ZS, Babor TF, et al. Psychopathology as a predictor of treatment outcome in alcoholics. Arch Gen Psychiatry. 1987;44:505-513.
48. Broome KM, Flynn PM, Simpson DD. Psychiatric comorbidity measures as predictors of retention in drug abuse treatment programs. Health Serv Res. 1999;34:791-806.
49. Broome KM, Joe GW, Simpson DD. HIV risk reduction in outpatient drug abuse treatment: individual and geographic differences. AIDS Educ Prev. 1999; 11:293-306.
50. Kosten TA, Kosten TR, Rounsaville BJ. Personality disorders in opiate addicts show prognostic specificity. J Subst Abuse Treat. 1989;6:163-168.
51. Rounsaville BJ, Kosten TR, Weissman MM, et al. Prognostic significance of psychopathology in treated opiate addicts. A 2.5-year follow-up study. Arch Gen Psychiatry. 1986;43:739-745.
52. Kosten TR, Rounsaville BJ, Kleber HD. A 2.5 year follow-up of treatment retention and reentry among opioid addicts. J Subst Abuse Treat. 1986;3:181-189.
53. Kokkevi A, Stefanis N, Anastasopoulou E, et al. Personality disorders in drug abusers: prevalence and their association with AXIS I disorders as predictors of treatment retention. Addict Behav. 1998;23: 841-853.
54. Alterman AI, Rutherford MJ, Cacciola JS, et al. Response to methadone maintenance and counseling in antisocial patients with and without major depression. J Nerv Ment Dis. 1996;184:695-702.
55. Alterman AI, Rutherford MJ, Cacciola JS, et al. Prediction of 7 months methadone maintenance treatment response by four measures of antisociality. Drug Alcohol Depend. 1998;49:217-223.
56. Darke S, Hall W, Wbdak A, et al. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict. 1992;87: 733-742.
57. Cacciola JS, Rutherford MJ, Alterman AI, et al. Personality disorders and treatment outcome in methadone maintenance patients. J Nerv Ment Dis. 1996;184:234-239.
58. Gerstley L, McLellan AT, Alterman AI, et al. Ability to form an alliance with the therapist: a possible marker of prognosis for patients with antisocial personality disorder. Am J Psychiatry. 1989;146: 508-512.
59. Woody GE, McLellan AT, Luborsky L, et al. Sociopathy and psychotherapy outcome. Arch Gen Psychiatry. 1985;42:1081-1086.
60. Brooner RK, Kidorf M, King VL, et al. Preliminary evidence of good treatment response in antisocial drug abusers. Drug Alcohol Depend. 1998;49:249-260.
61. Joe GW, Simpson DD, Hubbard RL. Treatment predictors of tenure in methadone maintenance. J Subst Abuse. 1991;3:73-84.
62. Rosenblum A, Magura S, Palij M, et al. Enhanced treatment outcomes for cocaine-using methadone patients. Drug Alcohol Depend. 1999;54:207-218.
63. Arndt IO, McLellan AT, Dorozynsky L, et al. Desipramine treatment for cocaine dependence. Role of antisocial personality disorder. J Nerv Ment Dis. 1994;182:151-156.
64. Leal J, Ziedonis D, Kosten T. Antisocial personality disorder as a prognostic factor for pharmacotherapy of cocaine dependence. Drug Alcohol Depend. 1994;35:31-35.
65. Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in Buprenorphine-versus methadone-maintained patients. J Nerv Ment Dis. 1998;186: 35-43.
66. Weizman T, Gelkopf M, Melamed Y, et al. Treatment of benzodiazepine dependence in methadone maintenance treatment patients: a comparison of two therapeutic modalities and the role of psychiatric comorbidity. Aust N Z J Psychiatry. 2003;37:458-463.
67. Rach-Beisel J, Scott J, Dixon L. Co-occurring severe mental illness and substance use disorders: a review of recent research. Psychiatr Serv. 1999;50:1427-1434.
68. Kosten TR, Rounsaville BJ. Psychopathology in opioid addicts. Psychiatr Clin North Am. 1986;9:515-532.
69. Kosten TR, Rounsaville BJ, Kleber HD. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch Gen Psychiatry. 1986;43:733-738.
70. Goldstein MF, Deren S, Kang SY, et al. Evaluation of an alternative program for MMTP drop-outs: impact on treatment re-entry. Drug Alcohol Depend. 2002; 66:181-187.
71. Rothbard A, Alterman A, Rutherford M, et al. Revisiting the effectiveness of methadone treatment on crime reductions in the 1990s. J Subst Abuse Treat. 1999;16:329-335.
72. Wong KH, Lee SS, Lim WL, et al. Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abuse Treat. 2003;24:233-239.
73. Caplehorn JR, Dalton MS, Cluff MC, et al. Retention in methadone maintenance and heroin addicts' risk of death. Addiction. 1994;89:203-209.
74. Esteban J, Gimeno C, Barril J, et al. Survival study of opioid addicts in relation to its adherence to methadone maintenance treatment. Drug Alcohol Depend. 2003;70:193-200.
75. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000;59:17-31.
76. D'Aunno T, Pollack HA. Changes in methadone treatment practices: results from a national panel Study, 1988-2000. JAMA. 2002;288:850-856.
77. Kaylor L. Antisocial personality disorder: diagnostic, ethical and treatment issues. Issues Ment Health Nurs. 1999;20:247-258.
78. Hser YI, Polinsky ML, Maglione M, et al. Matching clients' needs with drug treatment services. J Subst Abuse Treat. 1999;16:299-305.
79. McLellan AT, Luborsky L, Woody GE, et al. Predicting response to alcohol and drug abuse treatments. Role of psychiatric severity. Arch Gen Psychiatry. 1983; 40:620-625.
80. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953-1959.
81. Kosten TR, Schumann B, Wright D, et al. A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. J Clin Psychiatry. 1987;48:442-444.
82. Arndt IO, Dorozynsky L, Woody GE, et al. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch Gen Psychiatry. 1992;49:888-893.
83. Kosten TR, Morgan CM, Falcione J, et al. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry. 1992;49:894-898.
84. Margolin A, Kosten TR, Avants SK, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 1995;40:125-131.
85. Avants SK, Margolin A, DePhilippis D, et al. A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings. J Subst Abuse Treat. 1998;15:261-265.
86. Weiss RD, Mirin SM, Griffin ML. Methodological considerations in the diagnosis of coexisting psychiatric disorders in substance abusers. Br J Addict. 1992;87:179-187.
87. Strain EC, Stitzer ML, Bigelow GE. Early treatment time course of depressive symptoms in opiate addicts. J Nerv Ment Dis. 1991;179:215-221.
88. Substance Abuse and Mental Health Services Administration. Results from the 2002 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, editor. NHSDA Series H-22, DHHS Publication No. SMA 03-3836. Rockville, MD, 2003.